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ABSTRACT The in vitro leishmanicidal activities of a series of 48 recently synthe-
sized selenium derivatives against Leishmania infantum and Leishmania braziliensis
parasites were tested using promastigotes and intracellular amastigote forms. The
cytotoxicity of the tested compounds for J774.2 macrophage cells was also mea-
sured in order to establish their selectivity. Six of the tested compounds (com-
pounds 8, 10, 11, 15, 45, and 48) showed selectivity indexes higher than those of
the reference drug, meglumine antimonate (Glucantime), for both Leishmania spe-
cies; in the case of L. braziliensis, compound 20 was also remarkably selective. More-
over, data on infection rates and amastigote numbers per macrophage showed that
compounds 8, 10, 11, 15, 45, and 48 were the most active against both Leishmania
species studied. The observed changes in the excretion product proﬁle of parasites
treated with these six compounds were also consistent with substantial cytoplasmic
alterations. On the other hand, the most active compounds were potent inhibitors
of Fe superoxide dismutase (Fe-SOD) in the two parasite species considered,
whereas their impact on human CuZn-SOD was low. The high activity, low toxicity,
stability, low cost of the starting materials, and straightforward synthesis make these
compounds appropriate molecules for the development of affordable antileishmani-
cidal agents.
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Leishmaniasis, caused by the intracellular protozoan Leishmania, is transmitted bythe bite of phlebotomine sand ﬂies and is endemic in 98 countries, with over 350
million people being at risk (1). Environmental, demographic, and human behavioral
factors and coinfections contribute to the changing epidemiology of the disease and to
its recent worldwide spread. Clinical manifestations are divided into visceral leishman-
iasis (VL; or kala-azar) (2) and the forms cutaneous leishmaniasis (CL) and mucocuta-
neous leishmaniasis (ML). CL remains the most common form of leishmaniasis both in
general and in international travelers (3–5).
The drugs available for the treatment of VL and severe CL include pentavalent
antimonials (SbV), deoxycholate, amphotericin B (AMB), and miltefosine (MIL), all of
which have high levels of toxicity and/or require long-duration treatment schedules (5,
6). Moreover, with the exception of MIL, all these drugs must be administered by the
parenteral route (7).
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In the last decade, resistance to SbV has increased mainly due to low rates of
compliance with the treatment schedule. In areas where the parasites are resistant to
SbV, AMB is commonly used as it is very active but requires a month of hospitalization
for monitoring of renal function. MIL is highly active for the treatment of VL and well
tolerated, but its potential teratogenicity cannot be ruled out. Paromomycin (PM) is
actually in clinical trials for the treatment of leishmaniasis: it is effective, safe, and very
cheap, but 21 intramuscular (i.m.) injections are required. Other oral drugs include
azoles and allopurinol, but they did not reach the standards of efﬁcacy or safety. On the
basis of the available information, nowadays, a single dose of liposomal AMB is the best
available therapy for VL in India, as it is more effective and safer than any other
treatment. However, liposomal AMB seems to be less effective in Africa and for the
treatment of non-self-curing CL and ML (8, 9). Moreover, there are still the high price
and heat instability difﬁculties in their wide and safe distribution to primary health care
centers. Therefore, better treatments for leishmaniasis diseases are needed, and they
must be safer, cheaper, and easier to administer than the current drugs.
Recently, enzymes that are involved in evading the damage caused by oxidative
stress and that present substantial biochemical and structural differences from their
human counterparts have been reported to be interesting targets for novel antileish-
manial drugs (10). In this sense, the iron superoxide dismutase (Fe-SOD), an exclusive
antioxidant defense of trypanosomatids, is of special importance (11).
On the other hand, it is well-known that several of the most effective antiprotozoal
agents were originally developed as anticancer drugs. Thus, among the compounds
active against leishmaniasis, some antitumor drugs, such as cisplatin (12), miltefosine
(13), and tamoxifen (14), can be found.
In addition, the research activity of our group is focused on the synthesis of new
selenium (Se) compounds as antitumor agents, and we have intensively studied their
mechanisms of action, with some of them being found to be antioxidants (15–20).
Moreover, growing evidence suggests a connection between Se and parasites, partic-
ularly trypanosomatids (21–24).
In the light of the information mentioned above, different Se chemical entities with
proven antiproliferative activity against cancer (16, 25, 26) were chosen for testing as
leishmanicidal agents and were found to exhibit potent and selective effects against
some Leishmania species (27–30). Due to their antioxidant activity, the Fe-SOD enzyme
present in Leishmania spp. might be a plausible and good target for these compounds.
Encouraged by the promising results, we postulated that Se moieties can be central
scaffolds for designing new compounds for the treatment of infections caused by
leishmania. In this work, we report on the in vitro leishmanicidal activities (against
Leishmania infantum and L. braziliensis) of 48 selenocyanates and diselenides, as well as
their toxicity against macrophages, using meglumine antimonate (Glucantime) as a
reference drug. 1H nuclear magnetic resonance (NMR) analysis of the nature and
percentage of the excreted metabolites was performed to obtain information about the
inhibitory effect of our compounds on the glycolytic pathway, since this represents the
prime energy source of the parasite. Finally, the results of an evaluation of their
effectiveness as putative inhibitors of Fe-SOD in relation to human CuZn-SOD are also
presented.
RESULTS
Chemistry. The 48 compounds described in this work were synthesized in our
laboratory using previously published protocols (29–33). Their physical characteristics
and spectroscopic data are in agreement with the published data and are available in
the supplemental material.
Biological evaluation. (i) In vitro antileishmanial evaluation. In the ﬁrst step, we
assayed the in vitro biological activities of Se compounds 1 to 48 (Fig. 1) against both
the extra- and intracellular forms of two signiﬁcant species of Leishmania: L. infantum
(Table 1) and L. braziliensis (Table 2).
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Extracellular forms are more commonly used due to the ease of working with them,
but the activities of compounds against this form are less indicative of leishmanicidal
activity. The use of intracellular forms is more cumbersome but provides more accurate
results, as promastigotes are converted to amastigotes in vertebrate host cells (34, 35).
Intracellular assays were performed by infecting macrophage cells with promastigotes,
which transformed into amastigotes within 1 day after infection.
Table 1 shows the 50% inhibitory concentration (IC50) values obtained after 72 h of
exposure when the activities of compounds 1 to 48 against extra- and intracellular
forms of L. infantum were tested. IC50 values for toxicity against J774.2 macrophages
after 72 h were also calculated to establish the selectivity indexes (SIs). The results
obtained for the reference drug, meglumine antimonate, were included in all cases for
comparison. Biological data evidenced that half of the screened compounds (com-
pounds 8, 9, 10, 11, 13, 15, 17, 18, 20, 21, 24, 26, 29, 33, 35, 37, 38, 42, 43, 44, 45, 46,
47, and 48) showed high levels of bioactivity against L. infantum, presenting greater
potency than the reference drug, meglumine antimonate, against both forms (IC50s,
18.0 M for promastigotes and 24.2 M for amastigotes).
In order to obtain a more accurate picture of the features commented on above, we
show in Table 1 the SI values calculated from the IC50 data, since they are very
illustrative of the in vitro potential of the tested compounds with respect to that of the
reference drug. The number of times that the SI of each compound exceeded the SI of
meglumine antimonate is also shown in parentheses. The differences between meglu-
mine antimonate and the tested compounds are clearly revealed. Twelve compounds
(compounds 8, 10, 11, 15, 20, 21, 26, 31, 35, 44, 45, and 48) presented notable selectivity
index values (SIs  7) for both forms. These derivatives exhibited substantially better SI
values than the reference drug for L. infantum, and in the most remarkable case, the SI
FIG 1 Chemical structures of the Se compounds presented in this work. Comp., compound.
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TABLE 1 In vitro activities, toxicities, and SIs of the Se derivatives for extra- and
intracellular forms of Leishmania infantum
Compound
IC50a (M) for: SId
In vitro activityb
Macrophage
toxicityc
Promastigote
forms
Amastigote
forms
Promastigote
forms
Amastigote
forms
Meglumine
antimonate
18.0 3.1 24.2 2.6 15.2 1.0 0.8 0.6
1 44.1 5.2 31.7 2.0 92.6 5.1 2 (3) 3 (5)
2 38.7 2.9 23.8 2.0 5.9 0.6 0 (0) 0 (0)
3 36.5 2.7 17.9 1.4 61.5 3.5 2 (2) 3 (6)
4 41.8 4.1 16.9 0.9 24.7 2.2 0 (0) 1 (2)
5 23.9 1.7 18.6 1.7 19.6 1.7 0 (0) 1 (2)
6 19.4 1.6 10.4 0.6 29.7 2.6 1 (2) 3 (5)
7 35.9 3.5 28.9 2.2 44.8 3.0 1 (1) 2 (3)
8 0.7 0.2 3.7 0.6 132.8 7.5 190 (237) 36 (60)
9 13.8 0.9 8.3 0.4 51.3 4.1 4 (5) 6 (10)
10 2.1 0.5 4.6 1.0 139.9 8.3 67 (83) 30 (51)
11 1.9 0.3 3.8 0.7 62.9 4.4 33 (41) 17 (28)
12 23.8 1.1 16.4 1.3 8.2 0.7 0 (0) 0 (0)
13 3.5 0.6 6.1 0.3 10.1 0.9 3 (4) 1.6 (3)
14 28.5 1.9 14.8 0.9 9.5 1.1 0 (0) 1 (1)
15 0.8 0.1 2.7 0.3 49.4 3.5 62 (77) 18 (30)
16 23.7 2.6 11.7 0.8 19.2 0.7 0 (0) 2 (3)
17 16.7 0.8 10.3 0.7 19.3 1.2 1 (1) 2 (3)
18 3.6 0.7 5.5 0.6 14.7 1.2 4 (5) 2.6 (4)
19 41.9 2.5 18.7 1.3 70.0 4.7 2 (2) 4 (6)
20 2.7 0.8 3.7 0.4 29.5 2.4 11 (14) 8 (13)
21 1.2 0.2 0.9 0.0 8.3 0.4 7 (9) 9 (14)
22 37.8 2.5 17.5 1.2 27.4 0.9 0 (0) 2 (3)
23 47.0 5.3 19.1 1.6 60.3 4.7 1 (1) 3 (5)
24 6.5 0.7 3.6 0.5 11.8 0.8 2 (2) 3.3 (5)
25 18.4 0.5 14.8 0.7 72.4 5.5 4 (5) 5 (8)
26 6.6 0.4 4.1 0.7 47.9 3.1 7 (9) 11.7 (19)
27 28.6 2.5 20.5 1.7 112.3 7.3 4 (5) 11 (18)
28 83.6 6.8 37.8 2.4 74.2 6.6 0 (0) 2 (3)
29 7.1 0.8 4.2 1.0 22.7 1.6 3 (4) 5.4 (9)
30 26.7 2.0 18.7 1.1 64.0 3.0 2 (3) 3 (6)
31 16.8 1.2 16.8 0.9 185.9 81.6 11 (14) 11 (18)
32 16.5 2.0 13.3 0.8 44.6 2.4 3 (3) 3 (6)
33 7.9 0.6 4.9 0.8 44.1 3.7 6 (7) 9.0 (15)
34 19.7 1.2 15.2 1.1 34.8 2.4 2 (2) 2 (4)
35 3.9 0.7 4.3 0.6 41.8 2.7 11 (13) 10 (16)
36 23.3 1.7 21.6 1.3 59.3 3.7 2 (3) 3 (5)
37 4.8 1.2 2.6 0.2 17.3 0.7 4 (4) 6.6 (11)
38 13.6 0.8 8.9 0.4 78.4 5.7 6 (7) 9 (15)
39 36.5 3.4 30.0 2.2 50.7 3.8 1 (2) 2 (3)
40 25.8 2.7 17.7 1.4 36.2 2.4 1 (2) 2 (3)
41 19.0 1.1 21.8 1.2 9.6 1.3 0 (0) 0 (1)
42 2.5 0.6 3.2 0.3 18.7 0.6 7 (9) 5.8 (10)
43 8.9 0.7 5.8 1.1 28.5 3.8 3 (4) 4.9 (8)
44 4.4 0.3 3.9 0.6 33.4 3.0 8 (9) 8.6 (14)
45 3.7 0.5 2.7 0.3 61.1 4.1 16 (21) 23 (38)
46 8.6 0.8 6.3 1.3 29.7 1.8 3 (4) 4.7 (8)
47 1.1 0.5 2.7 0.5 12.6 0.8 11 (14) 5 (8)
48 1.6 0.1 1.4 0.2 52.8 3.61 33 (41) 38 (63)
aResults are the averages from four separate determinations.
bIC50, the concentration required to give 50% inhibition, calculated by linear regression analysis from the
values of the equilibrium constants (Kc) at the concentrations employed (1, 10, 25, and 200 M).
cToxicity against J774.2 macrophages after 72 h of culture.
dSI, selectivity index, which is calculated as the IC50 for macrophage toxicity/IC50 for activity against the
extracellular or intracellular form of the parasite. The number of times that the SI of the compound
exceeded the SI of the reference drug is provided in parentheses.
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TABLE 2 In vitro activities, toxicities, and SIs for the Se derivatives on extra- and
intracellular forms of Leishmania braziliensis
Compound
IC50a (M) for: SId
In vitro activityb
Macrophage
toxicityc
Promastigote
forms
Amastigote
forms
Promastigote
forms
Amastigote
forms
Meglumine
antimonate
25.6 1.7 30.4 2.6 15.2 1.0 0.6 0.6
1 43.9 3.7 31.8 2.5 92.6 5.1 2 (3) 3 (5)
2 21.7 2.3 16.8 1.1 5.9 0.6 0 (0) 0 (0)
3 20.8 1.2 17.9 1.3 61.5 3.5 3 (5) 3 (6)
4 37.53.5 26.4 1.6 24.7 2.2 0 (0) 1 (2)
5 15.8 0.6 9.6 0.4 19.6 1.7 1 (2) 2 (3)
6 16.8 1.1 16.8 0.9 29.7 2.6 2 (3) 2 (3)
7 30.7 1.6 22.7 1.6 44.8 3.0 1 (2) 2 (3)
8 1.3 0.3 3.8 0.6 132.8 7.5 102 (170) 35 (58)
9 10.8 0.7 9.4 1.4 51.3 4.1 5 (8) 5.4 (9)
10 4.4 0.1 5.7 0.8 139.9 8.3 32 (53) 24 (41)
11 1.6 0.4 2.8 0.5 62.9 4.4 39 (65) 22 (37)
12 22.7 1.8 15.8 0.8 8.2 0.7 0 (0) 0 (1)
13 4.5 0.4 5.8 1.5 10.1 0.9 2 (3) 1.7 (3)
14 20.7 1.3 19.8 1.3 9.5 1.1 0 (0) 0 (0)
15 0.6 0.1 1.4 0.3 49.4 3.5 82 (137) 35 (59)
16 16.9 1.2 11.7 0.6 19.2 0.7 1 (2) 2 (3)
17 10.5 1.0 8.5 2.0 19.3 1.2 2 (3) 2.3 (4)
18 2.1 0.1 1.9 0.1 14.7 1.2 7 (12) 7.7 (13)
19 8.9 0.6 10.4 1.3 70.0 4.7 8 (13) 7 (11)
20 1.3 0.3 1.1 0.2 29.5 2.4 23 (38) 27 (45)
21 2.0 0.3 1.3 0.2 8.3 0.4 4 (7) 6.4 (11)
22 9.6 1.2 7.5 1.2 27.4 0.9 3 (5) 3.6 (6)
23 20.8 2.5 17.7 0.8 60.3 4.7 3 (5) 3 (6)
24 5.7 0.4 4.3 0.9 11.8 0.8 2 (3) 2.7 (5)
25 13.9 2.0 10.6 1.7 72.4 5.5 5 (9) 7 (11)
26 4.3 0.3 4.8 0.3 47.9 3.1 11 (19) 10 (17)
27 18.4 1.2 12.8 0.4 112.3 7.3 6 (10) 9 (15)
28 37.4 3.4 23.6 1.8 74.2 6.6 2 (3) 3 (5)
29 6.6 0.5 4.2 0.8 22.7 1.6 3 (6) 5.4 (9)
30 20.5 0.9 13.8 0.8 64.0 3.0 3 (5) 5 (8)
31 20.9 2.6 19.7 1.2 185.9 81.6 9 (15) 9 (16)
32 13.7 0.7 6.8 0.2 44.6 2.4 3 (5) 6 (11)
33 6.9 0.6 4.9 0.7 44.1 3.7 6 (11) 9.0 (15)
34 14.5 1.8 10.6 1.7 34.8 2.4 2 (4) 3 (5)
35 2.5 0.7 2.4 0.6 41.8 2.7 17 (28) 17 (29)
36 17.8 0.7 12.2 0.4 59.3 3.7 3 (5) 5 (8)
37 3.7 0.5 2.4 0.4 17.3 0.7 5 (8) 7.2 (12)
38 15.8 0.9 9.9 0.5 78.4 5.7 5 (8) 8 (13)
39 31.5 3.5 17.6 1.4 50.7 3.8 2 (3) 3 (5)
40 24.7 1.7 20.1 2.3 36.2 2.4 2 (2) 2 (3)
41 11.9 1.3 10.8 0.5 9.6 1.3 0 (0) 0 (0)
42 4.7 0.2 3.3 0.6 18.7 0.6 4 (7) 5.7 (9)
43 4.7 0.6 3.7 0.5 28.5 3.8 6 (10) 7.7 (13)
44 2.8 0.8 4.3 0.8 33.4 3.0 8 (13) 10 (17)
45 1.7 0.1 2.0 0.5 61.1 4.1 36 (60) 30 (51)
46 3.3 0.4 3.4 0.7 29.7 1.8 9 (15) 9 (15)
47 0.8 0.2 1.0 0.1 12.6 0.8 16 (26) 13 (21)
48 0.9 0.1 1.8 0.5 52.8 3.6 59 (98) 29 (49)
aResults are the averages from four separate determinations.
bIC50, the concentration required to give 50% inhibition, calculated by linear regression analysis from the
values of the equilibrium constants (Kc) at the concentrations employed (1, 10, 25, and 200 M).
cToxicity against J774.2 macrophages after 72 h of culture.
dSI, selectivity index, which is calculated as the IC50 for macrophage toxicity/IC50 for activity against the
extracellular or intracellular form of the parasite. The number of times that the compound SI exceeded the
reference drug SI is provided in parentheses.
Novel Agents against Leishmania Species Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e02546-16 aac.asm.org 5
zac-aac/zac00617/zac6200d17z xppws S3 3/27/17 8:48 4/Color Fig: 8 ArtID: 02546-16 DOI:10.1128/AAC.02546-16CE: MKH
of compound 8 for the intracellular form of L. infantum exceeded that of meglumine
antimonate by 237-fold, a relevant data point, which was by far the best SI value.
Six of the compounds (compounds 8, 10, 11, 15, 45, and 48) stood out as the most
active and selective molecules, showing IC50s lower than 5 M along with SIs higher
than 15, and were selected for further studies.
Considering their activity against L. braziliensis (Table 2), the results recurred in the
two species and in both extra- and intracellular forms, since compounds 8, 10, 11, 15,
45, and 48 showed substantially better results, in terms of activity and selectivity, than
the rest of the tested compounds in all cases. For example, the SI of compound 8
exceeded that of the reference drug by 237- and 60-fold for the extra- and intracellular
forms ofL. infantum, respectively, and by 170- and 58-fold for the extra- and intracellular
forms ofL. braziliensis, respectively (Table 2). Compound 10 had an SI similar to that of
derivative 8, with the respective values obtained being 83- and 51-fold for L. infantum
(Table 1) and 53- and 41-fold for L. braziliensis (Table 2); compounds 11 and 15 were
equally effective against the two species of Leishmania and against both the extra- and
intracellular forms. Compound 11 had 41- and 28-fold increases in the SIs for the extra-
and intracellular forms ofL. infantum, respectively (Table 1), along with 65- and 37-fold
in SIs for the extra- and intracellular forms L. braziliensis, respectively (Table 2). On the
other hand, compounds 45 and 48 were more selective for the extracellular form of L.
braziliensis (Table 2). The rest of the tested compounds presented similar values in both
species, except compound 20, which was effective against L. braziliensis but not against
L. infantum.
(ii) Leishmanicidal activity in infected macrophages. In order to gain better
insight into the activities of the most active compounds, their effects on the infectivity
and intracellular replication of amastigotes were subsequently determined. Macro-
phage cells were grown and infected with promastigotes in the stationary phase. The
parasites invaded cells and underwent morphological conversion to amastigotes within
1 day after infection. On day 10, the rate of host cell infection reached its maximum
(control experiment). We used the IC25 of each product as the test dosage. Different
authors have claimed that compounds with SI values less than 20-fold those of the
reference drug should be discarded as candidates for more advanced leishmanicidal
tests due to their poor selectivity against mammalian cells (36). Therefore, we selected
the compounds that fulﬁlled this requirement (compounds 8, 10, 11, 15, 45, and 48 for
L. infantum and those compound plus compound 20 for L. braziliensis).
As shown in Fig. 2A and B, when the selected compounds were added to macro-
phages infected with L. infantum promastigotes, the infection rate decreased signiﬁ-
cantly with respect to that for the control; furthermore, the six compounds (compounds
8, 10, 11, 15, 45, and 48) were also remarkably more effective in decreasing infectivity
than meglumine antimonate. A measure of the average number of amastigotes per
infected macrophage (Fig. 2C and D) led to the same conclusion: all six compounds
were more effective than meglumine antimonate.
Infection rates (Fig. 3A and B) and the reduction in amastigote numbers (Fig. 3C and
D) obtained with L. braziliensis also showed that, in both cases, these six compounds
along with compound 20 were clearly more effective than meglumine antimonate, and
also in both cases, the order of effectiveness of the compounds was 48  45  8 
11  10  15  20  meglumine antimonate, since the reductions in the infectivity
rates calculated were 71%, 62%, 60%, 53%, 50%, 47%, 40%, and 28%, respectively. The
decreases in amastigote numbers were 70%, 66%, 60%, 53%, 48%, 48%, 43%, and 30%
for compounds 48, 45, 8, 11, 10, 15, and 20 and meglumine antimonate, respectively.
When these results are taken into account, it can be concluded that all compounds
analyzed were shown to be substantially more active than meglumine antimonate
against the two Leishmania species tested.
(iii) Studies on the mechanism of action. (a) Metabolite excretion effect. Since
trypanosomatids are unable to completely degrade glucose to CO2 under aerobic
conditions, they excrete much of the hexose skeleton into the medium as partially
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oxidized fragments in the form of fermented metabolites. The nature and percentages
of those excretion products depend on the pathway used for glucose metabolism by
each species (37).
The ﬁnal products of glucose catabolism in Leishmania are usually CO2, succinate,
acetate, D-lactate, L-alanine, and, in some cases, ethanol (37). Among them, succinate is
the most relevant, because its main role is to maintain the glycosomal redox balance,
allowing the reoxidation of NADH produced in the glycolytic pathway. Succinic fer-
mentation requires only half of the phosphoenolpyruvate produced to maintain the
NAD/NADH balance, and the remaining pyruvate is converted inside the mitochon-
drion and the cytosol into acetate, D-lactate, L-alanine, or ethanol, according to the
degradation pathway followed by a speciﬁc species (38).
We report below that the most active compounds caused great damage to the
mitochondria of the parasites of both Leishmania species, so that their highly disruptive
action presumably affected their glucose metabolism and, consequently, modiﬁed the
percentages of the ﬁnal excretion products formed. Therefore, we registered the 1H
NMR spectra of promastigotes from the L. infantum and L. braziliensis species after
treatment with the selected compounds, and the ﬁnal excretion products were iden-
tiﬁed qualitatively and quantitatively. The spectra obtained were compared with those
from promastigotes maintained in cell-free medium (control) for 4 days after inocula-
tion with the parasites. The variations in the areas of the signals corresponding to the
most signiﬁcant catabolites are displayed. The expected presence of acetate, D-lactate,
L-alanine, and succinate was conﬁrmed in the control experiments performed on both
species, and the major metabolite was succinate in all cases, in agreement with data
reported in the literature (38). However, relevant differences were found in parasites
treated with the derivatives, whereas the presence of meglumine antimonate did not
lead to signiﬁcant alterations in the energetic metabolism (data not shown).
Compounds 10, 11, and 20 induced increases in the levels of succinate production
in L. braziliensis (Fig. 4 and Table 3), as can be seen by measuring the area under the
succinate peak determined by 1H NMR. In the case of L. infantum, all the compounds
FIG 2 Effects of Se derivatives 8, 10, 11, 15, 45, and 48 on the rates of infection by and growth rates of L.
infantum. (A, B) Rates of infection; (C, D) mean numbers of amastigotes of L. infantum per infected J774.2
macrophage cell (when the compounds were tested at the IC25). Values are the means from three separate
experiments. Gluc., Glucantime (meglumine antimonate).
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increased the level of succinate production, although product 8 did so to a lesser extent
than the other compounds (Fig. 5 and Table 4). In fact, this succinate augmentation is
in agreement with transmission electron microscopy (TEM) evidence, indicating that
these derivatives severely damage the mitochondrial structures of the parasites (data
not shown).
(b) SOD enzymatic inhibition in Leishmania parasites and in human erythrocytes.
These results prompted us to evaluate the inhibitory effect of the most promising
compounds on the activity of Fe-SOD from L. infantum and L. braziliensis at concen-
trations ranging from 0.5 to 100 M.
FIG 3 Effects of Se derivatives 8, 10, 11, 15, 20, 45, and 48 on the rates of infection by and growth rates of
Leishmania braziliensis. (A, B) Rates of infection; (C, D) mean numbers of amastigotes of L. braziliensis per infected
J774 A.2 macrophage cell (when the compounds were tested at the IC25). Values are the means from three separate
experiments.
FIG 4 Variation in the area of the peaks (in percent) corresponding to metabolites excreted by L.
braziliensis forms in the presence of compounds 8, 10, 11, 15, 20, 45, and 48 at their IC25s compared to
the area for a control sample, determined by 1H NMR.
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To do so, we used the promastigote forms of both species, which excrete Fe-SOD
when cultured in a medium lacking inactive fetal bovine serum (39). The inhibition data
obtained are shown in Fig. 6A to D, and the corresponding IC50s are included for easier
evaluation of the graphs displayed. For comparison, the graphs in Fig. 7 show the
effects of the same compounds on CuZn-SOD obtained from human erythrocytes. The
most remarkable result was the signiﬁcant inhibitory effect of the highly leishmanicidal
compounds 8, 10, and 11 found on Fe-SOD from both species and compound 20 in the
case of L. braziliensis, whereas their inhibition of human CuZn-SOD was clearly lower.
If we consider the IC50 calculated for L. infantum, the levels of inhibition of Fe-SOD
by compounds 8, 10, and 11 were, respectively, 5-, 10- and 16-fold higher than the
levels of inhibition of CuZn-SOD, and in the case of L. braziliensis, the levels of inhibition
by compounds 8, 10, and 11 were 4-, 34-, and 0-fold higher, respectively, and the level
of inhibition by compound 20 was 9-fold higher.
DISCUSSION
The present results document the leishmanicidal effects of 48 Se derivatives. After
taking into consideration the IC50 data shown in Tables 1 and 2, it can be seen that
compounds 8, 10, 11, 15, 45, and 48 stand out as the molecules most active and
selective against the two Leishmania spp. studied (L. infantum and L. braziliensis).
Furthermore, they were much more active than meglumine antimonate against both
the extra- and intracellular forms of the parasite. Regarding the evaluation of cytotox-
icity against macrophage cells, it was also shown that these six compounds along with
compound 20 were clearly more selective than meglumine antimonate against L.
infantum and L. braziliensis. Attending to other studies to elucidate the possible
mechanisms of action, it should be noted that these compounds produced great
alterations in glucose metabolism in the studied species, according to the 1H NMR data
FIG 5 Variation in the area of the peaks (in percent) corresponding to metabolites excreted by L.
infantum promastigote forms in the presence of compounds 8, 10, 11, 15, 45, and 48 at their IC25s
compared to the area for a control sample, determined by 1H NMR.
TABLE 3 Variation in areas of peaks corresponding to catabolites excreted by L.
braziliensis promastigotes in presence of compounds with respect to those in control
tests
Compound
% variation in area of peaks
D-Lactate L-Alanine Acetate Pyruvate Succinate
Control 0.0 0.0 0.0 0.0 0.0
8 44.7 44.9 36.2 29.4 0.2
10 36.9 41.7 36.1 40.8 81.7
11 20.0 24.2 25.7 89.6 107.1
15 12.1 11.9 12.7 7.9 8.6
20 12.7 17.6 7.7 61.5 96.2
45 40.4 49.0 44.5 55.1 54.4
48 15.5 27.4 22.4 33.3 33.6
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for catabolites. It is feasible that the small size of these compounds allows them to
easily penetrate the cristae (tubular invaginations of the inner mitochondrial mem-
brane), leading to subsequent changes in the metabolic pathway, although further
studies are required to prove this point. In addition, these compounds led to important
levels of Fe-SOD inhibition. All these data seem to conﬁrm some kind of relation
between parasiticidal activity and inhibition of Fe-SOD, in accordance with results
described in a previous work (39). At another level, Fe-SOD inhibition could also be
related to the catabolic changes discussed above, since a mitochondrial malfunction
might originate from the redox stress produced by inhibition of the mitochondrion-
resident Fe-SOD enzyme (40). Since Fe-SOD is a speciﬁc chemotherapy target also
present in mitochondria, this fact would agree with the hypothesis presented above
TABLE 4 Variation in areas of peaks corresponding to catabolites excreted by L. infantum
promastigotes in presence of compounds with respect to those in control tests
Compound
% variation in area of peaks
D-Lactate L-Alanine Acetate Pyruvate Succinate
Control 0.0 0.0 0.0 0.0 0.0
8 20.4 22.5 18.8 17.0 18.6
10 1.8 4.8 1.1 8.3 102.1
11 48.8 41.8 30.6 80.7 118.9
15 58.1 50.7 27.8 91.3 132.1
45 44.6 34.2 35.4 90.3 474.1
48 36.0 25.7 30.3 91.1 153.6
FIG 6 In vitro inhibition (in percent) of Fe-SOD from L. infantum (A and B) and L. braziliensis (C and D) promastigote forms by the Se derivatives. The differences
between the activities of the control homogenate and homogenates incubated with the indicated compounds were obtained according to the Newman-Keuls
test. The concentrations in the keys are IC50s, which are the concentrations required to give 50% inhibition and which were calculated by linear regression
analysis from the values of the equilibrium constants (Kc) at the concentrations employed (0.5 to 100 M). The values are averages from three different
determinations.
Martín-Montes et al. Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e02546-16 aac.asm.org 10
AQ: Q AQ: Q
zac-aac/zac00617/zac6200d17z xppws S3 3/27/17 8:48 4/Color Fig: 8 ArtID: 02546-16 DOI:10.1128/AAC.02546-16CE: MKH
that these compounds might have a greater ability to pass through the mitochondrial
membrane.
From all the results detailed above, we conclude that the Se derivatives (compounds
8, 10, 11, 15, 45, and 48) show interesting in vitro leishmanicidal activity which seems
to be related to their ability to inhibit the parasite Fe-SOD. Interestingly, the 1H NMR
data for the catabolites are indicative of substantial alterations in glucose metabolism
in the studied species. In fact, this succinate augmentation is in agreement with
transmission electron microscopy (TEM) evidence indicating that these derivatives
severely damage the mitochondrial structures of the parasites (data not shown). A
graphical summary of the conclusions drawn from this work is presented in Fig. 8. On
that basis, we think that the activities of these compounds fulﬁll the requirements
needed to justify a more detailed investigation of the nature of the mechanisms
involved in their patterns of activity and, furthermore, that they could be considered
candidates for the study of their antiparasitic activities at a higher level. Finally, it is
worth mentioning that due to their different mechanisms of action, combined thera-
pies should be considered to obtain improved efﬁcacy.
MATERIALS AND METHODS
Chemistry. The Se compounds reported herein can be categorized into three groups (Fig. 1):
selenocyanate derivatives, or group I (compounds 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 28, 29, 30,
and 32); the diselenide analogs of the selenocyanate derivatives mentioned above, or group II (com-
pounds 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 31); and the diphenyldiselenide-derived
compounds bearing different sulfonamides substituted on the para position, or group III (compounds 33
to 48).
FIG 7 In vitro inhibition (in percent) of CuZn-SOD from human erythrocytes by the Se derivatives. The differences between the activities of the
control homogenate and homogenates incubated with the indicated compounds were obtained according to the Newman-Keuls test. The
concentrations in the keys are IC50s, which are the concentrations required to give 50% inhibition and which were calculated by linear regression
analysis from the values of the equilibrium constants (Kc) at the concentrations employed (0.5 to 100 M). The values are averages from three
different determinations.
FIG 8 Schematic illustration of conclusions.
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The group I compounds were obtained by the nucleophilic substitution of the halogen atom of the
corresponding alkyl or benzyl halides by a selenocyanate group using potassium selenocyanate (KSeCN)
under reﬂux conditions according to previously reported methods (29, 30). Thus, the corresponding
organic halide was reﬂuxed for 2 to 4 h in acetone with potassium selenocyanate. The resulting
precipitate was ﬁltered off, and the ﬁltrate was evaporated under vacuum. Then, the residue was treated
with water (2 times with 50 ml each time), ﬁltered, and dried. The solid obtained was puriﬁed either by
recrystallization or by washing with different solvents.
Group II derivatives were synthesized by reduction of the corresponding selenocyanate from group I
using sodium borohydride following the previously described procedure (29, 30). In order to do so, sodium
borohydride was added with caution to a stirring solution of the corresponding selenocyanate from group I
in absolute ethanol. After 2 h of reaction, the solvent was removed under reduced pressure and the residue
was treated with water (50 ml). The mixture was extracted with dichloromethane (3 times with 50 ml each
time); the organic fractions were collected, dried over sodium sulfate, and ﬁltered off; and the solvent was
removed under vacuum by rotary evaporation. The resulting solid was recrystallized using ethanol.
Finally, targeted compounds of group III were prepared from 4,4=-diselanediylaniline coupled to
different substituted sulfonyl chlorides (31). Brieﬂy, the corresponding sulfonyl chloride was added to a
mixture of 4,4=-diselanediylaniline and dry ether, and the reaction mixture was stirred at room temper-
ature for 48 to 72 h under a nitrogen atmosphere. The precipitate formed in the reaction mixture was
ﬁltered, dried, and puriﬁed accordingly by recrystallization or washing with different solvents.
Biological evaluation. (i) Determination of the potential leishmanicidal activity and toxicity of new
compounds. (a) Axenic cultures. The parasites were cultivated in axenic cultures using standard condi-
tions for the promastigote and amastigote forms of L. infantum (MCAN/ES/2001/UCM-10) and L.
braziliensis (MHOM/BR/1975/M2904) strains (41, 42).
(b) Cytotoxicity tests. The viability of J774.2 macrophages and Vero cells was determined by use of
a Coulter cell counter using previously published standardized methods (39).
(c) In vitro activity assays. For extracellular forms (promastigote assay), promastigotes were
collected in the exponential growth phase and distributed in culture trays (with 24 wells) at a ﬁnal
concentration of 5  104 parasites/well according to previously reported methods (39).
For intracellular forms (amastigote assay), macrophages of the J774.2 macrophage line (European
Collection of Cell Cultures [ECACC] number 91051511) were cultured in 24-well microplates with round
coverslips. The assays were performed as previously described (39).
(d) Infectivity assay. The mammalian cells were infected in vitro with metacyclic forms of Leishmania
spp. at a ratio of 10:1 according to information presented in the literature (39). At least three different
assays were performed to calculate the SI of each compound, which was determined as the ratio
between the IC50 obtained in macrophages and the corresponding IC50 in promastigotes.
(ii) Studies on the mechanism of action. (a) Metabolite excretion. According to previous reports
(39), cultures of extracellular forms received the selected compounds at a dose of the IC25 and were
then cultured for 72 h at 28°C. Then, the supernatant was collected to detect the excreted
metabolites by 1H NMR.
(b) Enzymatic inhibition of Fe-SOD. For SOD inhibition studies, the parasites cultured were centri-
fuged and processed as described previously (34, 35). Iron, manganese, and copper-zinc SOD activities
were determined using the method described by Beyer and Fridovich (43).
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